<DOC>
	<DOCNO>NCT00891579</DOCNO>
	<brief_summary>This study prospective trial Alimta ( pemetrexed ) versus IRESSA ( gefitinib ) among epidermal growth factor receptor wild-type Non-Small Cell Lung Cancer ( NSCLC ) patient 2nd line setting .</brief_summary>
	<brief_title>Study Pemetrexed Versus Gefitinib Patients With Locally Advanced Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor ( EGFR ) Mutations</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Informed consent must sign . 2 . At least 18 year age . 3 . Histologic cytologic diagnosis NSCLC . 4 . Locally advanced metastatic disease ( stage IIIB , IV ) amenable definitive surgery radiotherapy . 5 . Patients must previously receive one platinumbased chemotherapy regimen palliative therapy locally advance metastatic disease . Patients also eligible receive one platinumbased chemotherapy regimen neoadjuvant adjuvant chemotherapy disease recur within six month since finish neoadjuvant adjuvant chemotherapy . 6 . Without EGFR mutation . 7 . At least one measurable lesion define RECIST criterion . 8 . ECOG PS0 2 . 9 . Adequate organ function include follow : bone marrow ; hepatic ; renal . 10 . Prior chemotherapy must complete least 3 week prior study enrollment , patient must recover toxic effect treatment ( except alopecia ) . 11 . Previous palliative radiation therapy allow , limit LESS 25 % bone marrow must include whole pelvis radiation . Patients must recover toxic effect treatment prior study enrollment ( except alopecia ) . Prior radiotherapy must complete one month study entry . Radiotherapy administer target lesion select study , unless progression select target lesion within radiation portal document . 12 . Estimated life expectancy least 8 week . 13 . For woman : must surgically sterile ; postmenopausal ; OR compliant medically approve contraceptive regimen 3 month treatment period ; must negative serum urine pregnancy test must lactate . 14 . For men : must surgically sterile ; OR compliant contraceptive regimen 3 month treatment period . 15 . Patient compliance geographic proximity allow adequate followup . 1 . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry concurrent administration antitumor therapy . 2 . Have previously participate study involve pemetrexed EGFRTKI 3 . Hypersensitivity pemetrexed gefitinib ingredient two drug . 4 . Symptomatic central nervous system ( CNS ) metastases asymptomatic CNS metastasis require concurrent corticosteroid therapy . Treated stable CNS metastasis allow ; patient must stable radiotherapy 2 week corticosteroid 1 week . . 5 . History another malignancy within last 5 year except cured carcinoma insitu uterine cervix , cure basal cell carcinoma skin superficial bladder tumor ( Ta , Tis T1 ) 6 . Lack physical integrity upper gastrointestinal tract , malabsorption syndrome , inability take oral medication , active peptic ulcer disease . 7 . Patients interstitial lung disease . 8 . Any unstable systemic disease ( include active infection , hepatic , renal metabolic disease ) serious concomitant disorder would compromise safety patient , compromise patient 's ability complete study , discretion investigator . 9 . Significant cardiovascular event : congestive heart failure &gt; NYHA class 2 ; unstable angina , active CAD ( myocardial infarction 1 year prior study entry allow ) ; serious cardiac arrhythmia require antiarrythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension . 10 . History significant neurological mental disorder , include seizure dementia . 11 . Incision operation heal start study treatment ( Small incision biopsy eligible . ) 12 . Pregnant breastfeed woman childbearing potential woman either positive pregnancy test within 48 hour start treatment . Postmenopausal woman must amenorrhoeic least 12 month consider nonchildbearing potential . 13 . Concurrent use St. John 's Wort , Rifampicin , and/or ritonavir . 14 . Inability interrupt aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) 2 day , day , 2 day dose pemetrexed . If patient take NSAID ( Cox2 inhibitor include ) salicylate long halflife ( e.g. , naproxen , piroxicam , diflunisal , nabumetone , rofecoxib , celecoxib ) take 5 day , day , 2 day dose pemetrexed . 15 . Presence clinically detectable ( physical exam ) thirdspace fluid collection , example , ascites pleural effusion control drainage procedure prior study entry . 16 . Inability unwillingness take folic acid , vitamin B12 supplementation , dexamethasone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>EGFR</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Gefitinib</keyword>
	<keyword>without EGFR mutation</keyword>
</DOC>